Alzamend Neuro, Inc. entered into an At-the-Market Issuance Sales Agreement with Ascendiant Capital Markets, LLC on March 6, 2026, to sell up to $3.0 million of common stock through an ATM Offering pursuant to its effective Form S-3 registration statement. The Company filed a prospectus supplement with the SEC on the same date.
Key takeaways
Entered At-the-Market Issuance Sales Agreement on March 6, 2026
Sales agent: Ascendiant Capital Markets, LLC
Aggregate offering price: up to $3.0 million of common stock (par value $0.0001)
ATM Offering under Rule 415, Registration Statement No. 333-273610 (effective August 10, 2023)
Filed prospectus supplement with SEC on March 6, 2026